Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance

View ORCID ProfileRobert Flisiak, View ORCID ProfileDorota Zarębska-Michaluk, View ORCID ProfileMagdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, View ORCID ProfileKrystyna Dobrowolska, View ORCID ProfileJerzy Jaroszewicz, View ORCID ProfileAnna Moniuszko-Malinowska, View ORCID ProfileMarta Rorat, View ORCID ProfileRegina Podlasin, View ORCID ProfileOlga Tronina, View ORCID ProfilePiotr Rzymski
doi: https://doi.org/10.1101/2022.07.05.22277227
Robert Flisiak
1Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Flisiak
  • For correspondence: robert.flisiak1@gmail.com
Dorota Zarębska-Michaluk
2Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
3Provincial Hospital, Kielce, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dorota Zarębska-Michaluk
Magdalena Rogalska
1Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Magdalena Rogalska
Justyna Anna Kryńska
1Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justyna Kowalska
4Department of Adults’ Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ewa Dutkiewicz
5ZOZ, Busko Zdroj, Poland
6Jan Kochanowski University, Collegium Medicum, Kielce, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krystyna Dobrowolska
2Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Krystyna Dobrowolska
Jerzy Jaroszewicz
7Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jerzy Jaroszewicz
Anna Moniuszko-Malinowska
8Department of Infectious Diseases and Neuroinfections, Medical University of Białystok, Białystok, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Moniuszko-Malinowska
Marta Rorat
9Department of Forensic Medicine, Wrocław Medical University, Wrocław, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marta Rorat
Regina Podlasin
10IV-th Department, Hospital for Infectious Diseases, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Regina Podlasin
Olga Tronina
11Department of Transplantation Medicine, Nephrology, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olga Tronina
Piotr Rzymski
12Department of Environmental Medicine, Poznan University of Medical Sciences, Poznań, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Piotr Rzymski
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relates to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections.

Methods Among 11822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 31 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons

Results Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups.

Conclusions The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age.

Competing Interest Statement

Robert Flisiak and Jerzy Jaroszewicz reports grants and personal fees from MSD, Gilead, and Roche; Dorota Zarebska-Michaluk reports personal fees from MSD and Gilead; Justyna Kowalska reports grants and personal fees from MSD, Gilead, Janssen Cilag, GSK/ViiV and Roche; Anna Moniuszko-Malinowska reports personal fee from DiaSorin; Regina Podlasin reports personal fees from Gilead; Magdalena Rogalska, Justyna Anna Kryńska, Ewa Dutkiewicz, Krystyna Dobrowolska, Marta Rorat, Olga Tronina, Piotr Rzymski report no financial interests in relation to the work described

Funding Statement

This study was funded by Polish Association of epidemiologists and Infectiologists

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Bioethical Committee of Medical University of Bialystok

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

  • Abbreviations

    COVID-19
    coronavirus disease 2019
    CRP
    C-reactive protein
    ECMO
    extracorporeal membrane oxygenation
    FDA
    Food and Drug Administration
    NO AVT
    no antiviral therapy
    IL-6
    interleukin 6
    MOL
    molnupiravir
    PTEiLChZ
    Polish Association of Epidemiologists and Infectiologists
    RT-PCR
    real-time reverse transcriptase–polymerase chain reaction
    SARS-CoV-2
    severe acute respiratory syndrome coronavirus 2
    SpO2
    oxygen saturation
    WBC
    white blood cells
    WHO
    World Health Organization,
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted July 06, 2022.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
    Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, Jerzy Jaroszewicz, Anna Moniuszko-Malinowska, Marta Rorat, Regina Podlasin, Olga Tronina, Piotr Rzymski
    medRxiv 2022.07.05.22277227; doi: https://doi.org/10.1101/2022.07.05.22277227
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
    Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, Jerzy Jaroszewicz, Anna Moniuszko-Malinowska, Marta Rorat, Regina Podlasin, Olga Tronina, Piotr Rzymski
    medRxiv 2022.07.05.22277227; doi: https://doi.org/10.1101/2022.07.05.22277227

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (179)
    • Allergy and Immunology (433)
    • Anesthesia (99)
    • Cardiovascular Medicine (948)
    • Dentistry and Oral Medicine (178)
    • Dermatology (109)
    • Emergency Medicine (260)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
    • Epidemiology (8982)
    • Forensic Medicine (4)
    • Gastroenterology (419)
    • Genetic and Genomic Medicine (1949)
    • Geriatric Medicine (190)
    • Health Economics (401)
    • Health Informatics (1328)
    • Health Policy (659)
    • Health Systems and Quality Improvement (519)
    • Hematology (212)
    • HIV/AIDS (420)
    • Infectious Diseases (except HIV/AIDS) (10799)
    • Intensive Care and Critical Care Medicine (575)
    • Medical Education (200)
    • Medical Ethics (54)
    • Nephrology (222)
    • Neurology (1825)
    • Nursing (109)
    • Nutrition (272)
    • Obstetrics and Gynecology (353)
    • Occupational and Environmental Health (470)
    • Oncology (997)
    • Ophthalmology (297)
    • Orthopedics (111)
    • Otolaryngology (182)
    • Pain Medicine (126)
    • Palliative Medicine (44)
    • Pathology (265)
    • Pediatrics (579)
    • Pharmacology and Therapeutics (275)
    • Primary Care Research (234)
    • Psychiatry and Clinical Psychology (1896)
    • Public and Global Health (4120)
    • Radiology and Imaging (675)
    • Rehabilitation Medicine and Physical Therapy (368)
    • Respiratory Medicine (548)
    • Rheumatology (224)
    • Sexual and Reproductive Health (190)
    • Sports Medicine (177)
    • Surgery (207)
    • Toxicology (39)
    • Transplantation (109)
    • Urology (80)